Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PEG-IFN α-2b plus lenalidomide vs lenalidomide maintenance in MRD-positive multiple myeloma after consolidation
ChiCTR2100048763Phase 2Not yet recruiting
- Sponsor
- Henan Cancer Hospital
- Start
- Jul 2021
- Modality
- Small Molecules, Cytokines & Interferons → Recombinant Proteins and Enzymes, Biodegradable Polymers → Polymer-based Nanoparticles → Nanoparticles → Drug Delivery Systems
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of peginterferon alfa-2b and lenalidomide in multiple myeloma (MM) (2 arms), sponsored by Henan Cancer Hospital. Primary endpoint: Change in MRD level. Planned start Jul 2021; status: not yet recruiting.
02
Drugs
peginterferon alfa-2blenalidomide
03
Conditions
multiple myeloma (MM)
Beyond the preview
Go deeper on ChiCTR2100048763.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2100048763.